Harrow (HROW) is putting fresh clinical data in front of eye specialists, with 15 abstracts on its ophthalmic drugs scheduled across two major US optometry and ophthalmology meetings this month.
Harrow’s share price closed at US$30.62, with the stock down 38.65% on a year-to-date share price basis. The 3-year total shareholder return is a little over a double and the 5-year total shareholder return is roughly a triple, which suggests momentum has cooled recently as the market reassesses both growth potential and risk around the broader product portfolio, including these new clinical data readouts.
Spot new momentum or recovery setups in eyecare and beyond by scanning our curated list of 20 high quality undiscovered gems while you assess what these Harrow data readouts might mean for sentiment around the sector.For Harrow, the recent slide could signal investors cooling on the business or simply sentiment snapping back after a strong multi year run. At US$30.62, which story does the current valuation really tell?
Most Popular Narrative: 55% Undervalued
Harrow’s current share price of $30.62 sits well below the most followed narrative fair value estimate of $68.38, which frames the recent drawdown as a valuation gap rather than just a momentum break.
The rapidly growing demand for Harrow's portfolio of specialty ophthalmic drugs, particularly VEVYE, IHEEZO, and TRIESENCE, is positioned to accelerate further as aging populations and increased prevalence of chronic ocular diseases expand the baseline patient pool, supporting sustainable long-term revenue growth.
See why 15 investors see Harrow as 55% undervalued.
The narrative framework uses a 7.11% discount rate and ties that $68.38 fair value back to explicit assumptions on revenue, margins and earnings through to 2029. It rests on analysts modeling revenue of $784.8m and earnings of $246.0m by that point, with Harrow trading on a 13.3x P/E in those projections, which is below the current 15.3x P/E used for the broader US Pharmaceuticals group.
This approach places a lot of weight on Harrow’s ability to turn a current net loss of $37.2m into a much more profitable profile as its branded and biosimilar products scale across cataract surgery, ocular inflammation and retinal indications. It also assumes the existing commercial platform can absorb that higher volume efficiently so that forecast net profit margins of 31.3% hold in the model.
Result: Fair Value of $68.38 (UNDERVALUED)
Still, heavy reliance on VEVYE, IHEEZO and TRIESENCE, along with pressure on US drug pricing, could quickly challenge the Harrow undervaluation thesis.
Find out about the key risks to this Harrow narrative.
Next Steps
Debate around Harrow's recent slide and fair value is clearly split, so move quickly, review the full data set, and then pressure test your own thesis with the 3 key rewards.
Looking for more Harrow investment ideas?
Do not stop at Harrow. Broaden your watchlist now with focused stock ideas that match different risk levels, income needs, and value profiles across the market.
- Target potential mispricings by zeroing in on companies flagged as high quality and attractively valued through the 29 high quality undervalued stocks.
- Strengthen the income side of your portfolio by reviewing businesses in the 7 dividend fortresses that offer higher yields with supporting fundamentals.
- Dial down portfolio stress by concentrating on companies highlighted in the 31 resilient stocks with low risk scores that pair resilience scores with more robust balance sheets.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com